Resultados de Búsqueda
It is not recommended to administer lopinavir/ritonavir for people with COVID-19, only in the context of randomised trials with appropriate ethical approval.
Evidencias COVID-19
National COVID-19 Clinical Evidence Task Force
The Taskforce is continually monitoring research on antiviral and other disease-modifying treatments. As of 29 April 2020 we identified two randomised trials of lopinavir/ritonavir versus standard care (total 227 participants). As evidence accumulates regarding the use of lopinavir/ritonavir in the treatment of COVID-19, the Taskforce will continue to review and update this recommendation, including in special populations (e.g. children, pregnant women, people with immunosuppression or chronic ...
ver más ... 2020It is not recommended to administer hydroxychloroquine for people with COVID-19, only in the context of randomised trials with appropriate ethical approval.
Evidencias COVID-19
National COVID-19 Clinical Evidence Task Force
The Taskforce is continually monitoring research on antimalarial and other disease-modifying treatments. As of 29 April 2020 we identified three randomised trials of hydroxychloroquine versus standard care (total 242 participants). As evidence accumulates regarding the use of hydroxychloroquine in the treatment of COVID-19, the Taskforce will continue to review and update this recommendation, including in special populations (e.g. children, pregnant women, people with immunosuppression or ...
ver más ... 2020It is recommended to monitor markers of clinical progression, such as rapidly progressive respiratory failure and sepsis, especially on days 5 to 10 after onset of symptoms for people with COVID-19.
Evidencias COVID-19
National COVID-19 Clinical Evidence Task Force
This recommendation is not developed with an evidence based framework, but formed through a consensus process.
ver más ... 2020Ir is not recommended routinely determination of ultrasensitive Troponin T (hs-CTN) in patients with COVID-19 disease, without clinical suspicion of myocardial infarction and without compatible ...
Essencial: Afegint valor a la pràctica clínica [Essencial: Adding value to the clinical practice]
El Consorcio Sanitario de Terrassa
The increase in hs-CTN levels is multifactorial and not due to atherothrombotic coronary occlusion. This increase may be due to myocarditis, endothelial dysfunction-microvascular ischemia, stress cardiomyopathy, tachymocardiopathy, myocardial infarction type I, myocardial infarction type 2 (hypoxia, hypotension, tachycardia). Hs-CTN is a marker of myocardial damage. However, although it can be associated with an unfavorable evolution of the clinical situation, there are other clinical variables ...
ver más ... 2020It is not recommended routine determination of NT-ProBNP in patients with COVID-19 disease without clinical suspicion of acute heart failure or in a diagnostic study of dyspnea.
Essencial: Afegint valor a la pràctica clínica [Essencial: Adding value to the clinical practice]
El Consorcio Sanitario de Terrassa
NT-ProBNP is a marker of myocardial stress that tends to increase frequently in patients with severe respiratory diseases, usually in the absence of high filling pressures or clinical heart failure. This marker can be associated with an unfavorable evolution of the clinical situation, although there are other clinical variables that can guide this situation.
ver más ... 2020